Cancer is a heterogeneous disease, meaning every tumour may addict to distinct oncogenic mechanisms and therefore need personalised treatment. This complexity could arise from genomic alterations (e.g. mutations), microenvironment changes (e.g. immune cells) and their interactions. Nevertheless, current therapeutic development mainly focuses on one of these alterations, resulting poor response in many cases.
Dr Haonan Lu was previously trained in bioinformatics and cell biology at Imperial College London. He is particularly interested in developing imaging-based methods to describe cancer phenotypes, as well as discovering novel therapeutic targets through functional genomics approach.
et al., 2022, A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease, Communications Medicine, Vol:2, ISSN:2730-664X
et al., 2022, A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer's disease., Commun Med (lond), Vol:2
et al., 2021, Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC), British Journal of Cancer, Vol:126, ISSN:0007-0920, Pages:1047-1054
et al., 2021, Consideration of metabolite efflux in radiolabelled choline kinetics, Pharmaceutics, Vol:13, ISSN:1999-4923, Pages:1-18
et al., 2021, Novel non-congeneric derivatives of the choline kinase alpha inhibitor ICL-CCIC-0019, Pharmaceutics, Vol:13, ISSN:1999-4923, Pages:1-17